Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 29Recruiting 13Unknown 11Active not recruiting 8Not yet recruiting 6Withdrawn 4Terminated 4Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 10Cisplatin 7Bevacizumab 7pembrolizumab 6Radiosurgery 6Oxaliplatin 5Nivolumab 5Irinotecan 5Fluorouracil 5Everolimus 5Capecitabine 5Biopsy 5venetoclax 4fludarabine 4S 1 (combination) 4Prednisone 4Leucovorin 4Gemcitabine 4Etoposide 4Drug Therapy 4Doxorubicin 4Azacitidine 4fludarabine phosphate 3Vincristine 3Taxes 3Tacrolimus 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × OTHER × Tablets × Clear all
NCT02897050 2022-04-20

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Suspended
170 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡